CMMBChemomab Therapeutics Ltd.

$12M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$1M

Net Income

-$1M

EPS (Diluted)

$-7.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$10M

Total Liabilities

$2M

Stockholders' Equity

$8M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$1M	-$4M	+75.2%
Net Income	-$1M	-$2M	+40.2%

CMMB Q2 2020 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena